Related references
Note: Only part of the references are listed.An Open-Label, Single-Arm, Phase 2 Trial of the PoloLike Kinase Inhibitor Volasertib ( BI 6727) in Patients With Locally Advanced or Metastatic Urothelial Cancer
Walter M. Stadler et al.
CANCER (2014)
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
M. A. Dawson et al.
LEUKEMIA (2014)
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Pietro Ciceri et al.
NATURE CHEMICAL BIOLOGY (2014)
PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Sarah Picaud et al.
CANCER RESEARCH (2013)
Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Acute myeloid leukaemia in adults
Felicetto Ferrara et al.
LANCET (2013)
Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation
Mechthild Krause et al.
RADIOTHERAPY AND ONCOLOGY (2013)
BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
Helen Jayne Susan Stewart et al.
CANCER MEDICINE (2013)
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
K. Mross et al.
BRITISH JOURNAL OF CANCER (2012)
Small molecule inhibitor of polo-like kinase 1 (Plk1) causes significant melanoma growth delay and regression in vivo
Brian D. Cholewa et al.
CANCER RESEARCH (2012)
Prognostic PET 18F-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-Small Cell Lung Cancer
Viswam S. Nair et al.
CANCER RESEARCH (2012)
p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors
Mourad Sanhaji et al.
CELL CYCLE (2012)
Anti-tumor Activity of the PLK Inhibitor Volasertib (BI 6727) and the Aurora Kinase Inhibitor BI 811283 in Pediatric Malignancies
C. Lanvers-Kaminsky et al.
EUROPEAN JOURNAL OF CANCER (2012)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia?
Galina Tsykunova et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Acute myeloid leukemia in older adults
Masamitsu Yanada et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combination of Chemical Genetics and Phosphoproteomics for Kinase Signaling Analysis Enables Confident Identification of Cellular Downstream Targets
Felix S. Oppermann et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Histone Demethylase UTX and Chromatin Remodeler BRM Bind Directly to CBP and Modulate Acetylation of Histone H3 Lysine 27
Feng Tie et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
N. Anensen et al.
ONCOGENE (2012)
Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid
Rakel Brendsdal Forthun et al.
PLOS ONE (2012)
Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels
Jorg Haupenthal et al.
NEOPLASIA (2012)
Polo-like kinase 1 as target for cancer therapy
Lily Weiss et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2012)
Abstract 5414: Targeting prostate cancer through a combination of Polo-like kinase inhibitors and histone deacetylase inhibitors
Michel D. Wissing et al.
CANCER RESEARCH (2011)
Preclinical synergy of Plk1 inhibitors and HDACIs
Channing J. Paller et al.
CANCER RESEARCH (2011)
Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC
Rene H. Medema et al.
CLINICAL CANCER RESEARCH (2011)
Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Time to Step Out of the Limelight
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Utility of mTOR Inhibition in Hematologic Malignancies
Anas Younes et al.
ONCOLOGIST (2011)
Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells
Yu J. Chen et al.
PROTEOMICS (2011)
Quantitative Phosphoproteomics Identifies Substrates and Functional Modules of Aurora and Polo-Like Kinase Activities in Mitotic Cells
Arminja N. Kettenbach et al.
SCIENCE SIGNALING (2011)
Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia
J. Skavland et al.
BLOOD CANCER JOURNAL (2011)
Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. F. Fey et al.
ANNALS OF ONCOLOGY (2010)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Questions Regarding Frontline Therapy of Acute Myeloid Leukemia
Hagop Kantarjian et al.
CANCER (2010)
A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway?
Annelies G. Renner et al.
CELL CYCLE (2010)
An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
Ralf-Dieter Hofheinz et al.
CLINICAL CANCER RESEARCH (2010)
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2010)
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Sophie Park et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy Results from an Open-Label, Randomized Phase II Clinical Trial
Martin Sebastian et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
Yan Degenhardt et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
Clinical proteomics of myeloid leukemia
Sigrun M. Hjelle et al.
GENOME MEDICINE (2010)
AML in older patients: Are we making progress?
Elihu Estey
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Annelies G. Renner et al.
BLOOD (2009)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies
T. Ikezoe et al.
LEUKEMIA (2009)
Polo-like kinase 1 phosphorylates and regulates Bcl-xL during pironetin-induced apoptosis
Y. Tamura et al.
ONCOGENE (2009)
Polo-like kinase 1 is involved in invasion through extracellular matrix
Aylin Rizki et al.
CANCER RESEARCH (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression
M Lee et al.
ONCOGENE (2004)
Polo-like kinases and the orchestration of cell division
FA Barr et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
XQ Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
